The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
PRIMO 2025 | The neoadjuvant revolution: advancing cancer treatment with immunotherapy in a multimodal approach
Merrick Ross, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the role of multimodality therapy in cancer treatment, focusing on the evolving use of neoadjuvant approaches. He explains the different models of integrating systemic therapy with surgery—adjuvant (post-surgery), neoadjuvant (pre-surgery), and perioperative (both pre- and post-surgery)—highlighting how immunotherapy has revolutionized this treatment paradigm. Dr. Ross describes how immunotherapy, unlike chemotherapy, is more effective when given before surgery, as it primes the immune system and enhances long-term patient outcomes. He also explores the potential for optimizing complete pathologic response rates, reducing toxicity, and refining biomarker-driven treatment strategies. This interview took place at the PRIMO 2025 congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved
